GSK press releases Follow GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC) GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and CALM-2 phase III clinical trials https://www.gsk.com/en-gb/media/press-releases/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials/ gsk.com
